World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://www.wjon.org

Original Article

Volume 11, Number 5, October 2020, pages 216-222

Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer

Figures

Figure 1.
Figure 1. Three-year survival rate of 48 TNBC patients. TNBC: triple negative breast cancer.
Figure 2.
Figure 2. Kaplan-Meier survival curve of 48 TNBC patients. TNBC: triple negative breast cancer.
Figure 3.
Figure 3. Area under the ROC curve (a) and PD-L1 qRT-PCR result (b). ROC: receiver operating curve; PD-L1: programmed death-ligand 1 receptor; qRT-PCR: quantitative real-time polymerase chain reaction.
Figure 4.
Figure 4. Kaplan-Meier survival curve of PD-L1 in TNBC patients. PD-L1: programmed death-ligand 1 receptor; TNBC: triple negative breast cancer.

Tables

Table 1. The Clinicopathological Features of 48 TNBC Patients
 
CharacteristicNPercentage
TNBC: triple negative breast cancer; BMI: body mass index.
Age
  < 502143.80%
  ≥ 502756.30%
BMI
  < 231531.30%
  ≥ 233368.80%
Grouping stage
  Early breast cancer (I, II)2245.80%
  Locally advanced breast cancer (IIIA-IIIC)2654.20%
Histological grade
  Low grade1837.50%
  High grade3062.50%
Time interval from diagnosis to chemotherapy
  < 60 days2756.3%
  ≥ 60 days2143.8%
Chemotherapy regimen
  Platinum based2347.90%
  Anthracycline based2552.10%

 

Table 2. Determination of Optimal PD-L1 Cutoff Value
 
BiomarkerCutoff valueSensitivitySpecificityYouden indexAUC (95% CI)P
PD-L1: programmed death-ligand 1 receptor; AUC: area under the curve; CI: confidence interval.
PD-L146.87543.8%90.6%0.3440.586 (0.394 - 0.778)0.336

 

Table 3. Association Between PD-L1 Expression and Clinical Features in TNBC Patients
 
VariablesUnderexpression PD-L1Overexpression PD-L1P value
PD-L1: programmed death-ligand 1 receptor; TNBC: triple negative breast cancer; BMI: body mass index.
Age0.654
  < 50165
  ≥ 50225
Grouping BMI0.103
  < 23141
  ≥ 23249
Grouping stage0.565
  Early breast cancer (I, II)184
  Locally advanced breast cancer (IIIA-IIIC)206
Histological grade0.859
  Low grade144
  High grade246
Time interval from diagnosis to chemotherapy0.788
  < 60 days216
  ≥ 60 days174
Chemotherapy regimen0.763
  Platinum based194
  Anthracycline based196